{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(4)"],"submitter":["Janssen J"],"pubmed_abstract":["Treatment results of AML in elderly patients are unsatisfactory. We hypothesized that addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy may improve outcome in this population. After establishing a safe dose in a run-in phase of the study in 22 patients, 231 eligible patients with AML above 65 years of age (median 70, range 66-81) were randomly assigned in this open label randomized Phase II study to receive standard chemotherapy (3+7) with or without tosedostat at the selected daily dose of 120 mg (<i>n</i> = 116), days 1-21. In the second cycle, patients received cytarabine 1000 mg/m<sup>2</sup> twice daily on days 1-6 with or without tosedostat. CR/CRi rates in the 2 arms were not significantly different (69% (95% C.I. 60-77%) vs 64% (55-73%), respectively). "],"journal":["Cancers"],"pagination":["672"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7914531"],"repository":["biostudies-literature"],"pubmed_title":["Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS."],"pmcid":["PMC7914531"],"pubmed_authors":["Manz M","Nijziel M","Jie A","Spertini O","Kuball J","Hoogendoorn M","von dem Borne P","Graux C","Lammeren-Venema DV","Gregor M","Hess U","Oosterveld M","Velden WV","Vellenga E","Pabst T","Maertens J","Stussi G","Sinnige H","Poel MV","Brouwer R","Janssen J","Klein S","Tick L","Bargetzi M","Lowenberg B","Westerweel P","Norden YV","Klift MV","Moors I","Jongen-Lavrencic M","Deeren D","Weerdt O","Ossenkoppele G","Gjertsen BT","Breems D","Efthymiou A","Heim D","Terpstra W","Jaspers A","Vekemans MC","Chalandon Y","Obbergh FV","Kooy MVM","Biemond B","Legdeur MC","Loosdrecht AV"],"additional_accession":[]},"is_claimable":false,"name":"Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.","description":"Treatment results of AML in elderly patients are unsatisfactory. We hypothesized that addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy may improve outcome in this population. After establishing a safe dose in a run-in phase of the study in 22 patients, 231 eligible patients with AML above 65 years of age (median 70, range 66-81) were randomly assigned in this open label randomized Phase II study to receive standard chemotherapy (3+7) with or without tosedostat at the selected daily dose of 120 mg (<i>n</i> = 116), days 1-21. In the second cycle, patients received cytarabine 1000 mg/m<sup>2</sup> twice daily on days 1-6 with or without tosedostat. CR/CRi rates in the 2 arms were not significantly different (69% (95% C.I. 60-77%) vs 64% (55-73%), respectively). ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Feb","modification":"2026-05-03T01:31:19.09Z","creation":"2021-03-03T08:09:52Z"},"accession":"S-EPMC7914531","cross_references":{"pubmed":["33562393"],"doi":["10.3390/cancers13040672"]}}